Astrazeneca plc
NASDAQ: AZN
$78.53
-$0.37 (-0.5%)
Real Time Data Delayed 15 Min.
AZN Articles
Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability. One way to make up for the loss is to get US Food & Drug...
Published:
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Friday morning. Advanced Micro Devices, Inc. (NYSE: AMD) Raised to Market Perform at...
Published:
Last Updated:
We may have just witnessed an oversold bounce in the stock market, or we may be in for more days of recovery. The markets are flirting with six weeks of negative performance and one day is not...
Published:
Last Updated:
The drug sector has become rather boring and investors already know all about the ongoing patent expiration threats that loom in the industry. The good news is that the drug sector does still offer...
Published:
Last Updated:
American Depository Receipts, or ADRs, are generally called American Depository Shares, or ADSs, now. We found after some routine screens that there were many 3%, 4%, and 5% or higher dividend...
Published:
Last Updated:
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Wednesday morning. AstraZeneca plc (NYSE: AZN) Cut to Neutral at UBS. CenterPoint...
Published:
Last Updated:
The method of using capital from the corporate treasury to return capital to shareholders via share repurchase programs has long been under question. Most buybacks never are fully utilized, and...
Published:
Last Updated:
These are some of this Tuesday’s key analyst upgrades, downgrades, and initiations seen in Wall Street research calls. Amgen Inc. (NASDAQ: AMGN) Started as Neutral at Credit Suisse. AstraZeneca...
Published:
Last Updated:
These are some of this Wednesday’s top analyst upgrades, downgrades, and initiations seen in Wall Street research notes: Applied Materials Inc. (NASDAQ: AMAT) Started as Neutral at Susquehanna....
Published:
Last Updated:
There are many research calls this Thursday morning and these are just some of the top analyst upgrades, downgrades, and initiations seen in Wall Street research notes: Altria Group Inc. (NYSE: MO)...
Published:
Last Updated:
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research early this Wednesday. Some of the U.S. calls will get pretty thin as we get closer to July 4...
Published:
Last Updated:
We have an unusual cast of characters in this week’s version of THE UNUSUAL SUSPECTS for the week ahead, with almost none being tied to earnings. Some of the key stocks to watch with events ahead...
Published:
Last Updated:
The pharmaceutical industry has found a growing source of sales–the prescription of medicines, primarily used by adults in the past, to children. A portion of the sharp increase in drugs used by...
Published:
The FDA is routinely criticized for being a poor steward of drug research and pharmaceutical side effects. The agency proved once again why much of the criticism is justified. The FDA today said...
Published:
Last Updated:
These are Thursday’s top ten analyst research summary upgrades, downgrades, and initiations from Wall Street brokerage firms: AstraZeneca (AZN) Cut to Hold at Citigroup. Brandywine Realty (BDN) Cut...
Published: